NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016
Peter R. Carroll(UCSF Helen Diller Family Comprehensive Cancer Center), J. Kellogg Parsons(UC San Diego Health System), Gerald Andriole(Barnes-Jewish Hospital), Robert R. Bahnson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Erik P. Castle(WinnMed), William J. Catàlona(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Douglas M. Dahl(Massachusetts General Hospital), John W. Davis(The University of Texas MD Anderson Cancer Center), Jonathan I. Epstein(Sidney Kimmel Comprehensive Cancer Center), Ruth B. Etzioni(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Thomas Farrington(Education and Research Network), George P. Hemstreet(City Of Hope National Medical Center), Mark H. Kawachi(Bristol-Myers Squibb (Germany)), Simon Kim(Cleveland Clinic), Paul H. Lange(Seattle Cancer Care Alliance), Kevin R. Loughlin(Dana-Farber Brigham Cancer Center), William T. Lowrance(University of Utah), Paul Maroni(University of Colorado Cancer Center), James L. Mohler(Roswell Park Comprehensive Cancer Center), Todd M. Morgan(University of Michigan), Kelvin A. Moses(Bristol-Myers Squibb (Germany)), Robert B. Nadler(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Michael Poch(Moffitt Cancer Center), Chuck Scales(Cancer Institute (WIA)), Terrence Shaneyfelt(Fox Chase Cancer Center), Marc C. Smaldone(Fox Chase Cancer Center), Geoffrey A. Sonn, Preston C. Sprenkle(Yale Cancer Center), Andrew J. Vickers(Memorial Sloan Kettering Cancer Center), Robert Wake(St. Jude Children's Research Hospital), Dorothy A. Shead(National Comprehensive Cancer Network), Deborah A. Freedman-Cass(National Comprehensive Cancer Network)
Cited by 343Open Access
Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection provide recommendations for prostate cancer screening in healthy men who have elected to participate in an early detection program. The NCCN Guidelines focus on minimizing unnecessary procedures and limiting the detection of indolent disease. These NCCN Guidelines Insights summarize the NCCN Prostate Cancer Early Detection Panel's most significant discussions for the 2016 guideline update, which included issues surrounding screening in high-risk populations (ie, African Americans, BRCA1/2 mutation carriers), approaches to refine patient selection for initial and repeat biopsies, and approaches to improve biopsy specificity.